AbbVie's Upadacitinib Hits Primary Goal In Induction Study In Patients With Crohn's Disease

AbbVie Inc ABBV announced topline results from U-EXCEED, a Phase 3 induction study, of upadacitinib (45 mg once daily) in Patients with Crohn's Disease. The data achieved both primary endpoints of clinical remission and endoscopic response at week 12. 

• The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy.
• A significantly greater proportion of patients treated with a 12-week induction regimen of upadacitinib 45 mg daily achieved clinical remission at week 12 than placebo (39% versus 21%).
• Similar results were seen with clinical remission and endoscopic response (40% vs. 14%) and (35% versus 4%), respectively.
• Among patients taking corticosteroids at baseline, a significantly higher proportion of patients receiving upadacitinib 45 mg achieved steroid-free clinical remission than placebo at week 12.
• Related Link: AbbVie Adds New Warning To Rinvoq (JAK Inhibitor) Label For Rheumatoid Arthritis.
• Price Action: ABBV shares are up 2.21% at $121.46 during the market session on the last check Monday.